4SC AG (FSE: VSC)

http://www.4sc.com

4SC AG is a clinical-stage biopharmaceutical company developing small-molecule drugs that can target key indications in cancer with high unmet medical needs. 4SC’s pipeline is protected by a comprehensive portfolio of patents and currently comprises two drug candidates in clinical development: resminostat and domatinostat. 4SC aims to generate future growth and enhance its enterprise value by entering into partnerships with pharmaceutical and biotech companies and/or the eventual marketing and sales of approved drugs in select territories by 4SC itself. 4SC is headquartered in Planegg-Martinsried near Munich, Germany. The Company had 47 employees as of 31 March 2019 and is listed on the Prime Standard of the Frankfurt Stock Exchange (FSE Prime Standard: VSC; ISIN: DE000A14KL72). *

	Start	1997-01-01 established_pre
	Group	4SC (Group)
	Predecessor	4SC GmbH
	Industry	drug screening (HTS)
	Person	Loveridge, Jason (4SC 201609– CEO)
	Person 2	Doppler, Clemens (3i Germany 2007 Director Healthcare Team)

	Region	Martinsried
	Country	Germany
	Street	22 Fraunhoferstr.
	City	82152 Martinsried
	Tel	+49-89-700763-0
		Address record changed: 2018-07-24

Basic data	Employees	B: 11 to 50 (2019-03-31)
	Currency	EUR
	Annual sales	4,197,000 (revenue, consolidated (2017) 2017-12-31)
	Profit	-10,960,000 (2017-12-31)
	Cash	41,327,000 (2017-12-31)

		* Document for ï¿½About Sectionï¿½: 4SC AG. (6/28/19). "Press Release: 4SC AG Secures EUR 11 Million from Capital Increase [Ad hoc, not for US, AU, CA, JP, ZA, et al.]". Planegg-Martinsried.

		Record changed: 2020-01-01